Dynavax Technologies Corporation news

   Watch this stock
Showing stories 11 - 20 of about 74   

Articles published

DVAX 1.53 +0.06 (4.08%)
price chart
Sizzling News - Dynavax Technologies (NASDAQ:DVAX), Ibio Inc (NYSEMKT ...
Dynavax Technologies Corporation (NASDAQ:DVAX) reported its financial results for the first quarter ended March 31, 2014. The Company had $177.7 million in cash, cash equivalents and marketable securities as of March 31, 2014.
Eye-Catching Stocks - Dynavax Technologies Corporation (NASDAQ:DVAX ...
Miami, Florida - OCT18, 2014 - (Tech Sonian) -Dynavax Technologies Corporation (NASDAQ:DVAX) released initiation of a phase 1/2 clinical trial to assess the safety and preliminary efficacy of SD-101, an investigational Toll-like receptor (�TLR�) 9 ...
Short Interest in Dynavax Technologies Decreases By 4.3% (DVAX)
Dynavax Technologies (NASDAQ:DVAX) opened at 1.44 on Thursday. Dynavax Technologies has a 1-year low of $1.10 and a 1-year high of $2.14.
Trader's Watch List: Dynavax Technologies Corporation (DVAX), Interface ...  Techsonian (press release)
Related articles »  
Trending Stocks: Dynavax Technologies Corporation (NASDAQ:DVAX), Cesca ...
Boston, MA 10/14/2014 (wallstreetpr) - Dynavax Technologies Corporation (NASDAQ:DVAX) announced on 13th October that it had initiated phase 1/2 clinical trials of its drug candidate SD-101.
Stocks to Track- Dynavax Technologies Corporation (NASDAQ:DVAX), KB ...
Dynavax Technologies Corporation (NASDAQ:DVAX) advanced +6.30% and closed at $1.43 in the last trading session with the total traded volume of 5.03 million shares.
Key Announcements: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Dynavax ...  USMarketsDaily
Related articles »  
Eye-Catching Stocks-Newfield Exploration Co.(NYSE:NFX), Dynavax ...
(NYSE:NFX) an independent energy company, is engaged in the exploration, development, and production of crude oil, natural gas, and natural gas liquids.
Stocks Intraday Alert - Synergy Pharmaceuticals Inc (SGYP), Dynavax ...
Las Vegas, NV - 19 SEP, 2014 - (TechSonian) �Synergy Pharmaceuticals Inc (NASDAQ:SGYP) revealed that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic ...
Stocks On Radar: Genetic Technologies Limited (ADR) (NASDAQ:GENE ...
Dynavax Technologies Corporation (NASDAQ:DVAX), on September 22, in a press release announced the completion of its enrolment for the Phase 3 clinical trials for HEPLISAV-B.
Related articles »  
Stocks in Focus � Gevo, Inc. (NASDAQ:GEVO), Dynavax Technologies ...
Gevo, Inc. (GEVO) reported that the United States Patent and Trademark Office (�USPTO�) issued an inter partes review decision rejecting the claims of Gevo's U.S.
Stocks in News: Halliburton Company (NYSE:HAL), Peregrine Pharmaceuticals ...
Dynavax Technologies Corporation (NASDAQ:DVAX) said that it had commenced Phase 1/2 clinical study of TLR-9 Agonist Immunotherapy.
Related articles »